GalaxyVS, an AI virtual screening platform for ultra-large-scale drug discovery,
was officially launched in Tianjin today. Built on the new-generation Tianhe
supercomputing system, the platform can probe a near-100-billion synthesizable
compound space and implements an end-to-end stack covering molecular
representation, vector retrieval, diversity control, affinity re-ranking and
large-scale task scheduling. The platform is positioned to provide a
high-efficiency, high-precision, scalable foundational tool for innovative drugs
R&D and was developed by an AI biomed team led by Meng Xiangfei, chief scientist
at the National Supercomputing Center in Tianjin, and Lan Yanyan, professor at
Tsinghua University’s Institute for Intelligent Industry.
